Targeting the GAS5–miR-423-3p–SMARCA4 axis presents a novel and promising approach for HCC treatment, potentially improving patient outcomes by disrupting this critical oncogenic pathway. Here, SMARCA4 is linked to hepatocellular carcinoma.